Cargando…

Beyond SARS-CoV2, the role of viruses in the pathogenesis of hematologic malignancies

Detalles Bibliográficos
Autor principal:	Wiestner, Adrian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800017/ https://www.ncbi.nlm.nih.gov/pubmed/36805884 http://dx.doi.org/10.1053/j.seminhematol.2022.12.003

Ejemplares similares

SARS-CoV-2 vaccination in patients with solid tumors or hematological malignancies: Is the pandemic over for fully vaccinated patients?
por: Zojer, Niklas
Publicado: (2021)

HIV and SARS-CoV-2 Pathogenesis and Vaccine Development
por: Fleury, Herve
Publicado: (2022)

Special Issue “SARS-CoV-2: Epidemiology and Pathogenesis”: Editorial
por: Calistri, Paolo, et al.
Publicado: (2023)

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Malard, Florent, et al.
Publicado: (2021)

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
por: Greenberger, Lee M., et al.
Publicado: (2021)

Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination
por: Sriwijitalai, Won, et al.
Publicado: (2022)

The spectrum of pathological findings in coronavirus disease (COVID-19) and the pathogenesis of SARS-CoV-2
por: Barth, Rolf F., et al.
Publicado: (2020)

Within-host models of SARS-CoV-2: What can it teach us on the biological factors driving virus pathogenesis and transmission?
por: Prague, Mélanie, et al.
Publicado: (2022)

Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies
por: Tamariz-Amador, Luis-Esteban, et al.
Publicado: (2021)

SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
por: Haggenburg, Sabine, et al.
Publicado: (2022)

Sensitive detection of anti‐spike antibodies enables improved understanding of SARS‐CoV‐2 pathogenesis
por: Milling, Simon
Publicado: (2021)

Tripartite communication in COVID-19 infection: SARS-CoV-2 pathogenesis, gut microbiota and ACE2
por: Badi, Sara Ahmadi, et al.
Publicado: (2022)

Next-Generation Vaccines: Nanovaccines in the Fight against SARS-CoV-2 Virus and beyond SARS-CoV-2
por: Mufamadi, Maluta Steven, et al.
Publicado: (2023)

SARS-CoV-2: To be or not to be vaccinated?
por: Beauchet, Olivier
Publicado: (2021)

SARS-CoV-2 docet
por: Sarli, Leopoldo
Publicado: (2021)

Role of gastrointestinal system on transmission and pathogenesis of SARS-CoV-2
por: Simsek, Cem, et al.
Publicado: (2021)

Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections
por: Fani, Mona, et al.
Publicado: (2020)

Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2021)

1590P Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies
por: Zakurdaeva, K., et al.
Publicado: (2021)

Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination
por: Guven, Deniz C, et al.
Publicado: (2022)

SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies
por: Ni, Bin, et al.
Publicado: (2022)

SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research
por: Guven, Deniz C, et al.
Publicado: (2022)

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
por: Angotzi, Francesco, et al.
Publicado: (2023)

CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Adherence to Sars-CoV2 vaccination in hematological patients
por: Narinx, Justine, et al.
Publicado: (2022)

Caution is needed on the effect of altitude on the pathogenesis of SAR-CoV-2 virus()
por: Burtscher, Johannes, et al.
Publicado: (2020)

Does the pathogenesis of SARS-CoV-2 virus decrease at high-altitude?
por: Arias-Reyes, Christian, et al.
Publicado: (2020)

Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses
por: Nguyen, Tuan M., et al.
Publicado: (2020)

Poster: CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Is the Patient Infected with SARS-CoV-2?
por: Klausner, Jeffrey D., et al.
Publicado: (2021)

Fundamentals of SARS-CoV-2 Biosensors
por: Torres-Torres, Carlos, et al.
Publicado: (2022)

Terrific cells for SARS-CoV-2
por: Gottschalk, Stephen
Publicado: (2022)

Mechanisms of SARS-CoV-2 Transmission and Pathogenesis
por: Harrison, Andrew G., et al.
Publicado: (2020)

The pathogenesis and alternative treatment of SARS-CoV2
por: Choi, Jun-Yong, et al.
Publicado: (2020)

Epidemiology, transmission and pathogenesis of SARS-CoV-2
por: Sindhuja, Tulasi, et al.
Publicado: (2022)

Blood Research: hematology and beyond
por: Stroncek, David F.
Publicado: (2013)

The Role of Testing in Reducing SARS-CoV-2 Transmission on College Campuses
por: Barrios, Lisa C., et al.
Publicado: (2021)

Second-Generation SARS-CoV-2 Recombinants: Lessons from Other Viruses
por: Focosi, Daniele, et al.
Publicado: (2023)

IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection
por: Villegas, Carolina, et al.
Publicado: (2020)

Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR
por: Pelcovits, Ari, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v37lnerbl6hvv3vhv2oll30hi9